Jean M. Franchi, Chief Financial Officer of Disc Medicine (IRON 6.31%), executed open-market sales of 11,156 shares for approximately $720,000 across three transactions on Feb. 17 and Feb. 18, 2026, as disclosed in a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 11,156 |
| Transaction value | $720,000 |
| Post-transaction shares (direct) | 71,343 |
| Post-transaction value (direct ownership) | ~$4.6M |
Transaction value based on SEC Form 4 weighted average purchase price ($64.51); post-transaction value based on Feb. 18, 2026 weighted average price ($64.51).
Key questions
- How does this sale compare to Franchi's historical trading activity?
This sale of 11,156 shares is larger than any prior individual open-market transaction by Franchi, substantially exceeding the previous high of 3,136 shares in February 2024. - What proportion of Franchi's direct ownership was impacted?
The transaction accounted for 13.52% of direct holdings.
Company overview
| Metric | Value |
|---|---|
| Market capitalization | $2.51B |
| Employees | 142 |
| Net Loss (TTM) | $212.18M |
| 1-year price change (as of Feb | 22.33% |
NASDAQ: IRON
Key Data Points
Company snapshot
Disc Medicine is a clinical-stage biotechnology company specializing in the research, discovery, and development of therapies for serious hematologic diseases. The company leverages strong knowledge of red blood cell biology to focus on needs related to heme biosynthesis and iron homeostasis pathways.
What this transaction means for investors
Disc Medicine’s stock has seen modest gains over the last few years, seeing three years of consecutive price growth. However, the stock is down approximately 15% in 2026 (as of Feb. 28) and is at risk of falling further after one of its top clinical-stage drugs was rejected for approval by the U.S. Food and Drug Administration (FDA) on Feb. 13. The drug, bitopertin, is designed to be a treatment for a blood disorder that makes patients extremely sensitive to sunlight.
The rejection was largely due to the FDA’s concerns about the drug’s trial data and the risk of abuse. Disc Medicine’s FDA application for approval was submitted through the agency’s fast-track review program, which can shorten the review process from a year to just a month.
Disc is pursuing alternative approval pathways for bitopertin, but on Feb. 27, the company announced it was cutting 20% of its workforce due to the FDA rejection. The company also released its Q4 FY 2025 earnings report, with lackluster financials, including a doubling of its net loss for the entire fiscal year compared to the previous year.
